Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | withdrawn | Phase 2 | 91 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jul 14, 2009 | clinicaltrials |
| NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | completed | Phase 2 | 52 | Achieve Life SciencesINDUSTRY | 0 | Jun 4, 2009 | clinicaltrials |
| NCT00003135 | Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | unknown | Phase 2 | 34 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 30, 2009 | clinicaltrials |
| NCT00191334 | Gemcitabine in Ovarian Cancer | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 27, 2009 | clinicaltrials |
| NCT00204633 | Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) | completed | Phase 2 | 108 | University Hospital TuebingenOTHER | 1 | Feb 16, 2009 | clinicaltrials |
| NCT00113789 | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | completed | Phase 2 | 21 | AmgenINDUSTRY | 0 | Feb 13, 2009 | clinicaltrials |
| NCT00400348 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | completed | Phase 2 | 18 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00772798 | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | unknown | Phase 2 | 70 | Herlev HospitalOTHER | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00069901 | Phase II CT-2103/Carboplatin in Ovarian Cancer | completed | Phase 2 | 82 | CTI BioPharmaINDUSTRY | 1 | Sep 22, 2008 | clinicaltrials |
| NCT00075543 | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | unknown | Phase 1 / Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 24, 2008 | clinicaltrials |
| NCT00001427 | A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00034138 | A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | terminated | Phase 1 / Phase 2 | 24 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00034372 | Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma | terminated | Phase 2 | 102 | Unither PharmaceuticalsINDUSTRY | 2 | Dec 18, 2007 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00551577 | Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial(PRIMOVAR-1) | unknown | Phase 2 | 100 | University Hospital, BonnOTHER | 1 | Oct 31, 2007 | clinicaltrials |
| NCT00539669 | TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian | completed | Phase 2 | 47 | SanofiINDUSTRY | 1 | Oct 4, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00109096 | Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy | completed | Phase 2 | 100 | Eli Lilly and CompanyINDUSTRY | 4 | May 17, 2007 | clinicaltrials |
| NCT00074867 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | completed | Phase 2 | 29 | PfizerINDUSTRY | 2 | Nov 7, 2006 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00039793 | Massage Therapy for Cancer-Related Fatigue | completed | Phase 2 | 45 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00070967 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | completed | Phase 2 | 40 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | completed | Phase 2 | 75 | ARCAGY/ GINECO GROUPOTHER | 1 | Nov 3, 2005 | clinicaltrials |
| NCT00043446 | Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer. | unknown | Phase 2 | 35 | TularikINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00057395 | A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 40 | Aronex PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jul 14, 2009source: clinicaltrials